Local spin and charge properties of beta-Ag0.33V2O5 studied by 51V NMR

Local spin and charge properties were studied on beta-Ag0.33V2O5, a pressure-induced superconductor, at ambient pressure using 51V-NMR and zero-field-resonance (ZFR) techniques. Three inequivalent Vi sites (i=1, 2, and 3) were identified from 51V-NMR spectra and the principal axes of the electric-field-gradient (EFG) tensor were determined in a metallic phase and the following charge-ordering phase. We found from the EFG analysis that the V1 sites are in a similar local environment to the V3 sites. This was also observed in ZFR spectra as pairs of signals closely located with each other. These results are well explained by a charge-sharing model where a 3d1 electron is shared within a rung in both V1-V3 and V2-V2 two-leg ladders.Comment: 12pages, 16figure

The magnetic ordering in the mixed valence compound beta-Na0.33V2O5

The low-temperature electron spin resonance (ESR) spectra and the static magnetization data obtained for the stoichiometric single crystals of $\beta$-Na$_{0.33}$V$_2$O$_5$ indicate that this quasi-one-dimensional mixed valence (V4+/V5+) compound demonstrates at $T_N=22$ K the phase transition into the canted antiferromagnetically ordered state. The spontaneous magnetization of $3.4\times 10^{-3}$ $\mu_B$ per V$^{4+}$ ion was found to be oriented along the two-fold $b$ axis of the monoclinic structure, the vector of antiferromagnetism is aligned with the $a$ axis and the Dzyaloshinsky vector is parallel to the $c$-axis. The experimental data were successfully described in the frame of the macroscopic spin dynamics and the following values for the macroscopic parameters of the spin system were obtained: the Dzyaloshinsky field $H_D=6$ kOe, the energy gaps of two branches of the spin wave spectrum $\Delta_1=48$ GHz and $\Delta_2=24$ GHz.Comment: 5 pages, 6 figure

Efficacy and safety of vertebroplasty for treatment of painful osteoporotic vertebral fractures: a randomised controlled trial [ACTRN012605000079640]

Background. Vertebroplasty is a promising but as yet unproven treatment for painful osteoporotic vertebral fractures. It involves radiographic-guided injection of various types of bone cement directly into the vertebral fracture site. Uncontrolled studies and two controlled quasi-experimental before-after studies comparing volunteers who were offered treatment to those who refused it, have suggested an early benefit including rapid pain relief and improved function. Conversely, several uncontrolled studies and one of the controlled before-after studies have also suggested that vertebroplasty may increase the risk of subsequent vertebral fractures, particularly in vertebrae adjacent to treated levels or if cement leakage into the adjacent disc has occurred. As yet, there are no completed randomised controlled trials of vertebroplasty for osteoporotic vertebral fractures. The aims of this participant and outcome assessor-blinded randomised placebo-controlled trial are to i) determine the short-term efficacy and safety (3 months) of vertebroplasty for alleviating pain and improving function for painful osteoporotic vertebral fractures; and ii) determine its medium to longer-term efficacy and safety, particularly the risk of further fracture over 2 years. Design. A double-blind randomised controlled trial of 200 participants with one or two recent painful osteoporotic vertebral fractures. Participants will be stratified by duration of symptoms (< and ≥ 6 weeks), gender and treating radiologist and randomly allocated to either the treatment or placebo. Outcomes will be assessed at baseline, 1 week, 1, 3, 6, 12 and 24 months. Outcome measures include overall, night and rest pain on 10 cm visual analogue scales, quality of life measured by the Assessment of Quality of Life, Osteoporosis Quality of Life and EQ-5D questionnaires; participant perceived recovery on a 7-point ordinal scale ranging from 'a great deal worse' to 'a great deal better'; disability measured by the Roland-Morris Disability Questionnaire; timed 'Up and Go' test; and adverse effects. The presence of new fractures will be assessed by radiographs of the thoracic and lumbar spine performed at 12 and 24 months. Discussion. The results of this trial will be of major international importance and findings will be immediately translatable into clinical practice. Trial registration. Australian Clinical Trial Register # [ACTRN012605000079640]. © 2008 Buchbinder et al; licensee BioMed Central Ltd.Rachelle Buchbinder, Richard H Osborne, Peter R Ebeling, John D Wark, Peter Mitchell, Chris J Wriedt, Lainie Wengier, David Connell, Stephen E Graves, Margaret P Staples and Bridie Murph